

Ref #	Hits	Search Query	DBs	Default Operator	Plurals	Time Stamp
L1	2830	544/114, 544/238, 544/239, 514/236.5, 514/252.02, 514/252.03, 514/252.04, 514/252.05, 514/252.06	US-PGPUB; USPAT	OR	OFF	2005/10/19 14:55
L2	1831	CDK2	US-PGPUB; USPAT	OR	OFF	2005/10/19 14:53
L3	39	I1 and I2	US-PGPUB; USPAT	OR	OFF	2005/10/19 14:53
L4	2130	544/114, 544/238, 544/239, 514/236.5, 514/252.02, 514/252.03, 514/252.04, 514/252.05, 514/252.06	USPAT	OR	OFF	2005/10/19 14:55

chain bonds :

1-8 4-7 5-18 6-19 9-10 10-11 12-13 13-14

ring bonds :

1-2 1-6 2-3 3-4 4-5 5-6

exact/norm bonds :

1-2 1-6 1-8 2-3 3-4 4-5 4-7 5-6 5-18 9-10 10-11 12-13 13-14

exact bonds :

6-19

G2: [*1], [*2]

Match level :


1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:CLASS 8:Atom 9:CLASS 10:CLASS
11:CLASS 12:CLASS 13:CLASS 14:CLASS 18:CLASS 19:CLASS

L1 STRUCTURE UPLOADED

=> d l1

L1 HAS NO ANSWERS

L1 STR



G1

G2 [@1], [@2]

Structure attributes must be viewed using STN Express query preparation.

=> s l1

SAMPLE SEARCH INITIATED 08:42:39 FILE 'REGISTRY'

SAMPLE SCREEN SEARCH COMPLETED - 59 TO ITERATE

100.0% PROCESSED 59 ITERATIONS

9 ANSWERS

SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **COMPLETE**

BATCH **COMPLETE**

PROJECTED ITERATIONS: 720 TO 1640

PROJECTED ANSWERS: 9 TO 360

L2 9 SEA SSS SAM L1

<10/19/2005>

Habte

=> s l1 sss full

FULL SEARCH INITIATED 08:42:46 FILE 'REGISTRY'

FULL SCREEN SEARCH COMPLETED - 1173 TO ITERATE

100.0% PROCESSED 1173 ITERATIONS

103 ANSWERS

SEARCH TIME: 00.00.01

L3 103 SEA SSS FUL L1

=> file caplus

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

161.33

161.54

FILE 'CAPLUS' ENTERED AT 08:42:52 ON 19 OCT 2005

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2005 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 19 Oct 2005 VOL 143 ISS 17

FILE LAST UPDATED: 18 Oct 2005 (20051018/ED)

Effective October 17, 2005, revised CAS Information Use Policies apply.

They are available for your review at:

<http://www.cas.org/infopolicy.html>

=> s l3


L4 24 L3

=> d ibib abs hitstr tot

L4 ANSWER 1 OF 24 CAPLUS COPYRIGHT 2005 ACS on STN
 ACCESSION NUMBER: 2005:1004734 CAPLUS
 DOCUMENT NUMBER: 143:306326
 TITLE: Production of 4-benzimidazol-2-yl-pyridazin-3-one derivatives and use thereof in medicaments
 INVENTOR(S): Schoenafinger, Karl; Hoelder, Sven; Will, David; Williams, Matter, Hans; Mueller, Guenther; Bossart, Martin
 PATENT ASSIGNEE(S): Aventis Pharma Deutschland G.m.b.H., Germany
 SOURCE: FCT Int. Appl., 126 pp.
 CODENT: F1XXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: German
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005085230	A1	20050915	WO 2005-EP2179	20050302
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, BG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG DE 102004010194 A1 20051013 DE 2004-102004010194 20040302 PRIORITY APPL. INFO.: DE 2004-102004010194A 20040302 GI				

L4 ANSWER 1 OF 24 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)




AB The invention relates to compds. I [A = CR₃, N; B = CR₄, N; D = CR₅, N; E = CR₆, N; R₁ = halogen, un-, monosubstituted C1-10-alkyl, heterocyclyl, aryl, heteroaryl (optionally substituted with halogen, CN, NO₂, OR₇, COR₇, CO₂R₇, OC(=O)R₇, NR₇R₈, NHCOR₇, CONR₇R₈, NHCSR₇, CSNR₇R₈, SR₇, SOR₇, SO₂R₇, NHSO₂R₇, SO₂NR₇R₈, O-SO₂R₇, SO₂-OR₇, aryl, heteroaryl, heterocycle, CF₃, OCF₃]; R₂ = H, C1-10-alkyl; R₃, R₄, R₅, R₆ = H, halogen, CN, NO₂, CH₂R₈, CH₂NH₂, CH₂NH(C1-6-alkyl), CH₂N(C1-6-alkyl)₂, CH₂OH, CH₂O-(C1-6-alkyl), OR₈, COR₈, CO₂R₈, OC(=O)R₈, NR₇R₈, NHCOR₈, CONR₇R₈, NHCSR₈, CSNR₇R₈, SR₈, SOR₈, SO₂R₈, NHSO₂R₈, SO₂NR₇R₈, O-SO₂R₈, SO₂-OR₈, (un)substituted aryl, heteroaryl, heterocycle, CF₃, OCF₃; R₇, R₈ = H, un-monosubstituted C1-10-alkyl, C2-10-alkenyl, C2-10-alkynyl, heterocyclyl, aryl, heteroaryl; aryl = 5- to 10-membered aromatic mono- or bicyclic ring; heteroaryl = 5- to 10-membered aromatic mono- or bicyclic heterocycle with one or more heteroatoms - N, O, S; heterocycle = 5- to 10-membered non-aromatic mono- or bicyclic ring with one or more heteroatoms - N, O, S; with the proviso that up to three of A, B, D, E can equal N simultaneously; etc.] in addition to the physiol. compatible salts thereof, methods for the production of said compds. and the use thereof as medicaments. The procedure for the preparation of I comprises: reaction of pyridazinone II [Y = H, leaving group] with diamine III whereby cyclization takes place (a) in the presence of an acid or H₂O removing medium when Y = leaving group or (b) through oxidation, especially in the presence of O₂, when Y = H. Alternatively, I can be prepared from pyridazin-3-one IV [Y₁ = halogen, B(OH)₂, Sn(C1-10-alkyl)₃; Y₂ = H, protecting group] via palladium-catalyzed coupling with R1Z [Z = halogen, B(OH)₂, B(C1-10-alkyl)₂, Sn(C1-10-alkyl)₃, Zn(C1-10-alkyl)] followed by

L4 ANSWER 1 OF 24 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)
 deprotection of V (Y₂ = protecting group). Thus, 4-(6-(trifluoromethyl)-1H-benzimidazol-2-yl)-6-(pyridin-4-yl)-2H-pyridazin-3-one [I; A = B = E = CH, D = C-CF₃, R₁ = 4-pyridinyl, R₂ = H] was prepd. from 3-oxo-6-(pyridin-4-yl)-2,3-dihydropyridazin-4-carboxylic acid via chlorination with SOCl₂ in (MeOCH₂)₂, followed by amination with 4-(trifluoromethyl)benzene-1,2-diamine in (MeOCH₂)₂ contg. Et₃N and cyclocondensation of the amide in AcOH. Said compds. are kinase inhibitors, particularly inhibitors of kinase GSK-3β (glycogen synthase kinase-3β). The enzyme inhibitory activity of I [A = B = E = CH, D = C-CF₃, R₁ = 4-pyridinyl, R₂ = H] was detd. [IC₅₀ = 16 nM].
 IT 864464-06-2P
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
 (preparation and cyclocondensation of; preparation of 4-benzimidazol-2-yl-pyridazin-3-one derivs. with GSK-3β inhibitory activity)
 RN 864464-06-2 CAPLUS
 CN INDEX NAME NOT YET ASSIGNED



IT 864464-01-7P
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
 (preparation and cyclocondensation or saponification/cyclocondensation of; preparation of 4-benzimidazol-2-yl-pyridazin-3-one derivs. with GSK-3β inhibitory activity)
 RN 864464-01-7 CAPLUS
 CN INDEX NAME NOT YET ASSIGNED



L4 ANSWER 1 OF 24 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)


REFERENCE COUNT: 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 2 OF 24 CAPLUS COPYRIGHT 2005 ACS ON STN
 ACCESSION NUMBER: 2005:102888 CAPLUS
 DOCUMENT NUMBER: 143:286437
 TITLE: Preparation of 4-benzimidazol-2-yl-pyridazin-3-ones as cyclin dependent kinase 2 inhibitors
 PATENT ASSIGNEE(S): Aventis Pharma S. A., Fr.
 SOURCE: Ger. Offen., 37 pp.
 CODEN: GWXKEX
 DOCUMENT TYPE: Patent
 LANGUAGE: German
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
DE 102004010207	A1	20050915	DE 2004-102004010207	20040302
WO 2005085231	A1	20050915	WO 2005-EP2569	20050218

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
 RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

PRIORITY APPLM. INFO.: DE 2004-102004010207A 20040302
 GI



AB Title compds. I [A = CR3, N; B = CR4, N; D = CR5, N; E = CR8, N; R3, R4,

L4 ANSWER 3 OF 24 CAPLUS COPYRIGHT 2005 ACS ON STN
 ACCESSION NUMBER: 2004:411321 CAPLUS
 DOCUMENT NUMBER: 140:423683
 TITLE: Preparation of pyridazinones as protein Tau phosphorylation inhibitors, their drugs and pharmaceutical compositions containing them for treatment, in particular, of central and peripheral nervous system diseases
 INVENTOR(S): Lemaire, Dominique; Halley, Franck; Baudoin, Bernard; Rooney, Thomas; Hoelder, Sven; Naumann, Thorsten; Tiraboschi, Gilles
 PATENT ASSIGNEE(S): Aventis Pharma Sa, Fr.
 SOURCE: Fr. Demande, 65 pp.
 CODEN: FROXBL
 DOCUMENT TYPE: Patent
 LANGUAGE: French
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
FR 2847253	A1	20040521	FR 2002-14443	20021119
CA 2506022	AA	20040603	CA 2003-2506022	20031119
WO 2004046130	A1	20040603	WO 2003-EP12949	20031119

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW
 RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW
 RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG


US 2004176377 A1 20040909 US 2003-715358 20031119
 US 2005026918 A1 20050203 US 2003-715556 20031119
 EP 1581505 A1 20051005 EP 2003-775372 20031119

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK
 FR 2002-14443 A 20021119
 US 2003-43836P P 20030107
 WO 2003-EP12950 W 20031119


PRIORITY APPLM. INFO.: MARPAT 140:423683
 GI

OTHER SOURCE(S): MARPAT 140:423683
 GI



L4 ANSWER 2 OF 24 CAPLUS COPYRIGHT 2005 ACS ON STN (Continued)
 R5 = H, halo, CN, etc.; R1 = halo, alkyl; R2 = H, alkyl; R8 = H, alkyl, alkenyl, etc.] and their pharmaceutically acceptable salts and formulations were prepd. For example, sapon. of Me ester II (X = OMe) afforded claimed carboxylic acid II (X = OH). In cyclin dependent kinase 2 inhibition assays, 3-examples of compds. I exhibited IC50 values ranging from 0.026-0.214 µM.
 IT 864464-01-7P 864464-06-2P
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
 (preparation of benzimidazolylpyridazinones as cyclin dependent kinase 2 inhibitors)
 RN 864464-01-7 CAPLUS
 CN INDEX NAME NOT YET ASSIGNED



RN 864464-06-2 CAPLUS
 CN INDEX NAME NOT YET ASSIGNED




L4 ANSWER 3 OF 24 CAPLUS COPYRIGHT 2005 ACS ON STN (Continued)




AB Title compds. I [wherein A = CONHR, or NHCOR; R = (un)substituted heteroaryl/aryl/alkyl, hetero/aryl, fused hetero/aryl with cycloalkyl, etc.; Ar = (un)substituted aryl, Ph, pyridinyl; and their racemates, enantiomers, diastereomers, mixts., tautomers and pharmaceutically acceptable salts] were prepared as protein Tau phosphorylation inhibitors. Three standard pharmaceutical compds. are given. For example, II was prepared by acylation of 3-Oxo-6-phenyl-2,3-dihydropyridazine-4-carboxylic acid with 2,4-dichlorobenzylamine. Selected invention compds. I inhibited phosphorylation of protein Tau with an IC50 < 100 µM. Thus, I and their pharmaceutical compns. are useful as kinase inhibitors and for treatment, in particular, of central and peripheral nervous system diseases (no data).
 IT 691848-75-6P, N-(2,4-Dichlorobenzyl)-3-oxo-6-[4-(benzyloxy)phenyl]-2,3-dihydropyridazine-4-carboxamide 691848-77-8P, N-Benzyl-3-oxo-6-[4-(hydroxy)phenyl]-2,3-dihydropyridazine-4-carboxamide
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
 (intermediate; preparation of pyridazinones as protein Tau phosphorylation inhibitors for treating central and peripheral nervous system diseases)
 RN 691848-75-6 CAPLUS
 CN 4-Pyridazinocarboxamide, N-[(2,4-dichlorophenyl)methyl]-2,3-dihydro-3-oxo-6-[4-(phenylmethoxy)phenyl]- (9CI) (CA INDEX NAME)

L4 ANSWER 3 OF 24 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)




RN 691848-77-8 CAPLUS
CN 4-Pyridazinedicarboxamide, 2,3-dihydro-6-(4-hydroxyphenyl)-3-oxo-N-(phenylmethyl)- (9CI) (CA INDEX NAME)




IT 691848-21-2P, N-(2,4-Dichlorobenzyl)-3-oxo-6-phen-4-yl-2,3-dihydropyridazine-4-carboxamide 691848-24-5P, N-(2,4-Dichlorobenzyl)-3-oxo-6-(pyridin-4-yl)-2,3-dihydropyridazine-4-carboxamide 691848-28-9P, N-Benzyl-3-oxo-6-(pyridin-4-yl)-2,3-dihydropyridazine-4-carboxamide 691848-31-4P, N-(4-Chlorobenzyl)-3-oxo-6-(pyridin-4-yl)-2,3-dihydropyridazine-4-carboxamide 691848-33-6P, N-(2-Chlorobenzyl)-3-oxo-6-(pyridin-4-yl)-2,3-dihydropyridazine-4-carboxamide 691848-36-9P, N-[2-(2,4-Dichlorophenyl)ethyl]-3-oxo-6-(pyridin-4-yl)-2,3-dihydropyridazine-4-carboxamide 691848-38-1P, N-(2,4-Dichlorophenyl)-3-oxo-6-(pyridin-4-yl)-2,3-dihydropyridazine-4-carboxamide 691848-41-6P, 3-Oxo-6-(pyridin-4-yl)-N-[(pyridin-4-yl)methyl]-2,3-dihydropyridazine-4-carboxamide 691848-43-8P, 3-Oxo-6-(pyridin-4-yl)-N-[3-(trifluoromethyl)benzyl]-2,3-dihydropyridazine-4-carboxamide 691848-45-0P, 3-Oxo-6-(pyridin-4-yl)-N-[4-(trifluoromethyl)benzyl]-2,3-dihydropyridazine-4-carboxamide 691848-47-2P, N-(3,5-Dichlorobenzyl)-3-oxo-6-(pyridin-4-yl)-2,3-dihydropyridazine-4-carboxamide 691848-49-4P, 3-Oxo-6-(pyridin-4-yl)-N-(n-butyl)-2,3-dihydropyridazine-4-carboxamide 691848-51-8P, 3-[[[3-Oxo-6-(pyridin-4-yl)-2,3-dihydropyridazin-4-yl]carbonyl]amino]propionic acid ethyl ester 691848-53-0P, 3-Oxo-6-(pyridin-4-yl)-N-(pyridin-3-ylmethyl)-2,3-dihydropyridazine-4-carboxamide 691848-55-2P, 3-Oxo-6-(pyridin-4-yl)-N-[(pyridin-2-yl)methyl]-2,3-dihydropyridazine-4-carboxamide 691848-57-4P, N-(3,4-Dichlorobenzyl)-3-oxo-6-(pyridin-4-yl)-2,3-dihydropyridazine-4-

L4 ANSWER 3 OF 24 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)
carboxamide 691848-59-6P, N-[4-(Morpholin-4-yl)benzyl]-3-oxo-6-(pyridin-4-yl)-2,3-dihydropyridazine-4-carboxamide 691848-67-6P, N-(4-Hydroxybenzyl)-3-oxo-6-(pyridin-4-yl)-2,3-dihydropyridazine-4-carboxamide 691848-79-0P, N-(2,4-Dichlorobenzyl)-3-oxo-6-[4-(hydroxy)phenyl]-2,3-dihydropyridazine-4-carboxamide 691848-81-4P, N-(2,4-Dichlorobenzyl)-3-oxo-6-(3-benzyl-4-hydroxyphenyl)-2,3-dihydropyridazine-4-carboxamide 691848-89-2P, N-(2,4-Dichlorobenzyl)-3-oxo-6-(pyridin-2-yl)-2,3-dihydropyridazine-4-carboxamide 691848-99-4P, N-(2,4-Dichlorobenzyl)-3-oxo-6-(pyridin-3-yl)-2,3-dihydropyridazine-4-carboxamide 691849-03-3P, N-(4-Chlorobenzyl)-3-oxo-6-[4-(hydroxy)phenyl]-2,3-dihydropyridazine-4-carboxamide 691849-04-4P, N-(2-Chlorobenzyl)-3-oxo-6-[4-(hydroxy)phenyl]-2,3-dihydropyridazine-4-carboxamide 691849-05-5P, N-[2-(2,4-Dichlorophenyl)ethyl]-3-oxo-6-[4-(hydroxy)phenyl]-2,3-dihydropyridazine-4-carboxamide 691849-06-6P, N-(2,4-Dichlorophenyl)-3-oxo-6-[4-(hydroxy)phenyl]-2,3-dihydropyridazine-4-carboxamide 691849-07-7P, 3-Oxo-6-[4-(hydroxy)phenyl]-N-(pyridin-4-ylmethyl)-2,3-dihydropyridazine-4-carboxamide 691849-08-8P, 3-Oxo-6-[4-(hydroxy)phenyl]-N-[3-(trifluoromethyl)benzyl]-2,3-dihydropyridazine-4-carboxamide 691849-09-9P, 3-Oxo-6-[4-(hydroxy)phenyl]-N-[4-(trifluoromethyl)benzyl]-2,3-dihydropyridazine-4-carboxamide 691849-10-2P, N-(3,5-Dichlorobenzyl)-3-oxo-6-[4-(hydroxy)phenyl]-2,3-dihydropyridazine-4-carboxamide 691849-11-3P, 3-Oxo-6-[4-(hydroxy)phenyl]-N-(n-butyl)-2,3-dihydropyridazine-4-carboxamide 691849-12-4P, 3-Oxo-6-[4-(hydroxy)phenyl]-N-(pyridin-3-ylmethyl)-2,3-dihydropyridazine-4-carboxamide 691849-13-5P, 3-Oxo-6-[4-(hydroxy)phenyl]-N-(pyridin-2-ylmethyl)-2,3-dihydropyridazine-4-carboxamide 691849-14-6P, N-(3,4-Dichlorobenzyl)-3-oxo-6-[4-(hydroxy)phenyl]-2,3-dihydropyridazine-4-carboxamide 691849-15-7P, N-[4-(Morpholin-4-yl)benzyl]-3-oxo-6-[4-(hydroxy)phenyl]-2,3-dihydropyridazine-4-carboxamide 691849-16-8P, N-(4-Hydroxybenzyl)-3-oxo-6-[4-(hydroxy)phenyl]-2,3-dihydropyridazine-4-carboxamide 691849-17-9P, N-(2,4-Dichlorobenzyl)-3-oxo-6-[4-(hydroxy)pyridin-3-yl]-2,3-dihydropyridazine-4-carboxamide 691849-18-0P, N-Benzyl-3-oxo-6-[4-(hydroxy)pyridin-3-yl]-2,3-dihydropyridazine-4-carboxamide 691849-19-1P, N-(4-Chlorobenzyl)-3-oxo-6-[4-(hydroxy)pyridin-3-yl]-2,3-dihydropyridazine-4-carboxamide 691849-20-4P, N-(2-Chlorobenzyl)-3-oxo-6-[4-(hydroxy)pyridin-3-yl]-2,3-dihydropyridazine-4-carboxamide 691849-21-5P, N-[2-(2,4-Dichlorophenyl)ethyl]-3-oxo-6-[4-(hydroxy)pyridin-3-yl]-2,3-dihydropyridazine-4-carboxamide 691849-22-6P, N-(2,4-Dichlorophenyl)-3-oxo-6-[4-(hydroxy)pyridin-3-yl]-2,3-dihydropyridazine-4-carboxamide 691849-23-7P, 3-Oxo-6-[4-(hydroxy)pyridin-3-yl]-N-(pyridin-4-ylmethyl)-2,3-dihydropyridazine-4-carboxamide 691849-24-8P, 3-Oxo-6-[4-(hydroxy)pyridin-3-yl]-N-[3-(trifluoromethyl)benzyl]-2,3-dihydropyridazine-4-carboxamide 691849-25-9P, 3-Oxo-6-[4-(hydroxy)pyridin-3-yl]-N-[4-(trifluoromethyl)benzyl]-2,3-dihydropyridazine-4-carboxamide 691849-26-0P, N-(3,5-Dichlorobenzyl)-3-oxo-6-[4-(hydroxy)pyridin-3-yl]-2,3-dihydropyridazine-4-carboxamide 691849-27-1P, 3-Oxo-6-[4-(hydroxy)pyridin-3-yl]-N-(n-butyl)-2,3-dihydropyridazine-4-carboxamide 691849-28-2P, 3-Oxo-6-[4-(hydroxy)pyridin-3-yl]-N-(pyridin-3-ylmethyl)-2,3-dihydropyridazine-4-carboxamide

L4 ANSWER 3 OF 24 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)
691849-29-3P, 3-Oxo-6-[4-(hydroxy)pyridin-3-yl]-N-(pyridin-2-ylmethyl)-2,3-dihydropyridazine-4-carboxamide 691849-30-6P, N-(3,4-Dichlorobenzyl)-3-oxo-6-[4-(hydroxy)pyridin-3-yl]-2,3-dihydropyridazine-4-carboxamide 691849-31-7P, N-[4-(Morpholin-4-yl)benzyl]-3-oxo-6-[4-(hydroxy)pyridin-3-yl]-2,3-dihydropyridazine-4-carboxamide 691849-32-8P, N-(4-Hydroxybenzyl)-3-oxo-6-[4-(hydroxy)pyridin-3-yl]-2,3-dihydropyridazine-4-carboxamide 691849-33-9P, N-(2,4-Dichlorophenyl)-N-[3-oxo-6-(pyridin-4-yl)-2,3-dihydropyridazin-4-yl]acetamide 691849-34-0P, N-(2,4-Dichlorobenzyl)-3-oxo-6-(pyrimidin-4-yl)-2,3-dihydropyridazine-4-carboxamide (protein Tau phosphorylation inhibitor; prepn. of pyridazinones as protein Tau phosphorylation inhibitors for treating central and peripheral nervous system diseases)
RN 691848-21-2 CAPLUS
CN 4-Pyridazinedicarboxamide, N-[(2,4-dichlorophenyl)methyl]-2,3-dihydro-3-oxo-6-phenyl- (9CI) (CA INDEX NAME)




RN 691848-24-5 CAPLUS
CN 4-Pyridazinedicarboxamide, N-[(2,4-dichlorophenyl)methyl]-2,3-dihydro-3-oxo-6-(4-pyridinyl)- (9CI) (CA INDEX NAME)




RN 691848-28-9 CAPLUS
CN 4-Pyridazinedicarboxamide, 2,3-dihydro-3-oxo-N-(phenylmethyl)-6-(4-pyridinyl)- (9CI) (CA INDEX NAME)


L4 ANSWER 3 OF 24 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 691848-31-4 CAPLUS
CN 4-Pyridazinedicarboxamide, N-[(4-chlorophenyl)methyl]-2,3-dihydro-3-oxo-6-(4-pyridinyl)- (9CI) (CA INDEX NAME)




RN 691848-33-6 CAPLUS
CN 4-Pyridazinedicarboxamide, N-[(2-chlorophenyl)methyl]-2,3-dihydro-3-oxo-6-(4-pyridinyl)- (9CI) (CA INDEX NAME)




RN 691848-36-9 CAPLUS
CN 4-Pyridazinedicarboxamide, N-[(2,4-dichlorophenyl)ethyl]-2,3-dihydro-3-oxo-6-(4-pyridinyl)- (9CI) (CA INDEX NAME)


L4 ANSWER 3 OF 24 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 691848-38-1 CAPLUS
CN 4-Pyridazinecarboxamide, N-(2,4-dichlorophenyl)-2,3-dihydro-3-oxo-6-(4-pyridinyl)- (9CI) (CA INDEX NAME)




RN 691848-41-6 CAPLUS
CN 4-Pyridazinecarboxamide, 2,3-dihydro-3-oxo-6-(4-pyridinyl)-N-(4-pyridinylmethyl)- (9CI) (CA INDEX NAME)




RN 691848-43-8 CAPLUS
CN 4-Pyridazinecarboxamide, 2,3-dihydro-3-oxo-6-(4-pyridinyl)-N-[(3-(trifluoromethyl)phenyl)methyl]- (9CI) (CA INDEX NAME)


L4 ANSWER 3 OF 24 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 691848-45-0 CAPLUS
CN 4-Pyridazinecarboxamide, 2,3-dihydro-3-oxo-6-(4-pyridinyl)-N-[(4-(trifluoromethyl)phenyl)methyl]- (9CI) (CA INDEX NAME)




RN 691848-47-2 CAPLUS
CN 4-Pyridazinecarboxamide, N-[(3,5-dichlorophenyl)methyl]-2,3-dihydro-3-oxo-6-(4-pyridinyl)- (9CI) (CA INDEX NAME)




RN 691848-49-4 CAPLUS
CN 4-Pyridazinecarboxamide, N-butyl-2,3-dihydro-3-oxo-6-(4-pyridinyl)- (9CI) (CA INDEX NAME)


L4 ANSWER 3 OF 24 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)




RN 691848-51-8 CAPLUS
CN beta-Alanine, N-[(2,3-dihydro-3-oxo-6-(4-pyridinyl)-4-pyridazinyl)carbonyl]-, ethyl ester (9CI) (CA INDEX NAME)



RN 691848-53-0 CAPLUS
CN 4-Pyridazinecarboxamide, 2,3-dihydro-3-oxo-6-(4-pyridinyl)-N-(3-pyridinylmethyl)- (9CI) (CA INDEX NAME)




RN 691848-55-2 CAPLUS
CN 4-Pyridazinecarboxamide, 2,3-dihydro-3-oxo-6-(4-pyridinyl)-N-(2-pyridinylmethyl)- (9CI) (CA INDEX NAME)




L4 ANSWER 3 OF 24 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)


RN 691848-57-4 CAPLUS
CN 4-Pyridazinecarboxamide, N-[(3,4-dichlorophenyl)methyl]-2,3-dihydro-3-oxo-6-(4-pyridinyl)- (9CI) (CA INDEX NAME)



RN 691848-59-6 CAPLUS
CN 4-Pyridazinecarboxamide, 2,3-dihydro-N-[(4-(4-morpholinyl)phenyl)methyl]-3-oxo-6-(4-pyridinyl)- (9CI) (CA INDEX NAME)




RN 691848-67-6 CAPLUS
CN 4-Pyridazinecarboxamide, 2,3-dihydro-N-[(4-hydroxyphenyl)methyl]-3-oxo-6-(4-pyridinyl)- (9CI) (CA INDEX NAME)




RN 691848-79-0 CAPLUS
CN 4-Pyridazinecarboxamide, N-[(2,4-dichlorophenyl)methyl]-2,3-dihydro-6-(4-hydroxyphenyl)-3-oxo- (9CI) (CA INDEX NAME)


L4 ANSWER 3 OF 24 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 691848-81-4 CAPLUS
CN 4-Pyridazinecarboxamide, N-[(2,4-dichlorophenyl)methyl]-2,3-dihydro-6-(4-hydroxy-3-(phenylmethyl)phenyl)-3-oxo- (9CI) (CA INDEX NAME)




RN 691848-89-2 CAPLUS
CN 4-Pyridazinecarboxamide, N-[(2,4-dichlorophenyl)methyl]-2,3-dihydro-3-oxo-6-(2-pyridinyl)- (9CI) (CA INDEX NAME)




RN 691848-99-4 CAPLUS
CN 4-Pyridazinecarboxamide, N-[(2,4-dichlorophenyl)methyl]-2,3-dihydro-3-oxo-6-(2-pyridinyl)- (9CI) (CA INDEX NAME)


L4 ANSWER 3 OF 24 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 691849-03-3 CAPLUS
CN 4-Pyridazinecarboxamide, N-[(2-chlorophenyl)methyl]-2,3-dihydro-6-(4-hydroxyphenyl)-3-oxo- (9CI) (CA INDEX NAME)




RN 691849-04-4 CAPLUS
CN 4-Pyridazinecarboxamide, N-[(2-chlorophenyl)methyl]-2,3-dihydro-6-(4-hydroxyphenyl)-3-oxo- (9CI) (CA INDEX NAME)




L4 ANSWER 3 OF 24 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)

RN 691849-05-5 CAPLUS
CN 4-Pyridazinecarboxamide, N-[(2,4-dichlorophenyl)ethyl]-2,3-dihydro-6-(4-hydroxyphenyl)-3-oxo- (9CI) (CA INDEX NAME)



RN 691849-06-6 CAPLUS
CN 4-Pyridazinecarboxamide, N-[(2,4-dichlorophenyl)ethyl]-2,3-dihydro-6-(4-hydroxyphenyl)-3-oxo- (9CI) (CA INDEX NAME)




RN 691849-07-7 CAPLUS
CN 4-Pyridazinecarboxamide, N-[(2,4-dichlorophenyl)ethyl]-2,3-dihydro-6-(4-hydroxyphenyl)-3-oxo- (9CI) (CA INDEX NAME)




RN 691849-10-2 CAPLUS
CN 4-Pyridazinecarboxamide, N-[(2,4-dichlorophenyl)ethyl]-2,3-dihydro-6-(4-hydroxyphenyl)-3-oxo- (9CI) (CA INDEX NAME)


L4 ANSWER 3 OF 24 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 691849-11-3 CAPLUS
CN 4-Pyridazinecarboxamide, N-butyl-2,3-dihydro-6-(4-hydroxyphenyl)-3-oxo- (9CI) (CA INDEX NAME)




RN 691849-12-4 CAPLUS
CN 4-Pyridazinecarboxamide, 2,3-dihydro-6-(4-hydroxyphenyl)-3-oxo-N-(3-pyridinylmethyl)- (9CI) (CA INDEX NAME)




RN 691849-13-5 CAPLUS
CN 4-Pyridazinecarboxamide, 2,3-dihydro-6-(4-hydroxyphenyl)-3-oxo-N-(2-pyridinylmethyl)- (9CI) (CA INDEX NAME)


L4 ANSWER 3 OF 24 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 691849-14-6 CAPLUS
CN 4-Pyridazinecarboxamide, N-[(3,4-dichlorophenyl)methyl]-2,3-dihydro-6-(4-hydroxyphenyl)-3-oxo- (9CI) (CA INDEX NAME)




RN 691849-15-7 CAPLUS
CN 4-Pyridazinecarboxamide, 2,3-dihydro-6-(4-hydroxyphenyl)-N-[(4-morpholinyl)phenylmethyl]-3-oxo- (9CI) (CA INDEX NAME)




RN 691849-16-8 CAPLUS
CN 4-Pyridazinecarboxamide, 2,3-dihydro-6-(4-hydroxyphenyl)-N-[(4-hydroxyphenyl)methyl]-3-oxo- (9CI) (CA INDEX NAME)


L4 ANSWER 3 OF 24 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 691849-17-9 CAPLUS
CN 4-Pyridazinecarboxamide, N-[(2,4-dichlorophenyl)methyl]-2,3-dihydro-6-(4-hydroxy-3-pyridinyl)-3-oxo- (9CI) (CA INDEX NAME)




RN 691849-18-0 CAPLUS
CN 4-Pyridazinecarboxamide, 2,3-dihydro-6-(4-hydroxy-3-pyridinyl)-3-oxo-N-(phenylmethyl)- (9CI) (CA INDEX NAME)




RN 691849-19-1 CAPLUS
CN 4-Pyridazinecarboxamide, N-[(4-chlorophenyl)methyl]-2,3-dihydro-6-(4-hydroxy-3-pyridinyl)-3-oxo- (9CI) (CA INDEX NAME)


L4 ANSWER 3 OF 24 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 691849-20-4 CAPLUS
CN 4-Pyridazinecarboxamide, N-[(2-chlorophenyl)methyl]-2,3-dihydro-6-(4-hydroxy-3-pyridinyl)-3-oxo- (9CI) (CA INDEX NAME)




RN 691849-21-5 CAPLUS
CN 4-Pyridazinecarboxamide, N-[2-(2,4-dichlorophenyl)ethyl]-2,3-dihydro-6-(4-hydroxy-3-pyridinyl)-3-oxo- (9CI) (CA INDEX NAME)




RN 691849-22-6 CAPLUS
CN 4-Pyridazinecarboxamide, N-(2,4-dichlorophenyl)-2,3-dihydro-6-(4-hydroxy-3-pyridinyl)-3-oxo- (9CI) (CA INDEX NAME)


L4 ANSWER 3 OF 24 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 691849-23-7 CAPLUS
 CN 4-Pyridazinecarboxamide, 2,3-dihydro-6-(4-hydroxy-3-pyridinyl)-3-oxo-N-(4-pyridinylmethyl)- (9CI) (CA INDEX NAME)




RN 691849-24-8 CAPLUS
 CN 4-Pyridazinecarboxamide, 2,3-dihydro-6-(4-hydroxy-3-pyridinyl)-3-oxo-N-[(3-trifluoromethyl)phenylmethyl]- (9CI) (CA INDEX NAME)




RN 691849-25-9 CAPLUS
 CN 4-Pyridazinecarboxamide, 2,3-dihydro-6-(4-hydroxy-3-pyridinyl)-3-oxo-N-[(4-trifluoromethyl)phenylmethyl]- (9CI) (CA INDEX NAME)


L4 ANSWER 3 OF 24 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 691849-29-3 CAPLUS
 CN 4-Pyridazinecarboxamide, 2,3-dihydro-6-(4-hydroxy-3-pyridinyl)-3-oxo-N-(2-pyridinylmethyl)- (9CI) (CA INDEX NAME)




RN 691849-30-6 CAPLUS
 CN 4-Pyridazinecarboxamide, N-[(3,4-dichlorophenyl)methyl]-2,3-dihydro-6-(4-hydroxy-3-pyridinyl)-3-oxo- (9CI) (CA INDEX NAME)




RN 691849-31-7 CAPLUS
 CN 4-Pyridazinecarboxamide, 2,3-dihydro-6-(4-hydroxy-3-pyridinyl)-N-[(4-(4-morpholinyl)phenyl)methyl]-3-oxo- (9CI) (CA INDEX NAME)


L4 ANSWER 3 OF 24 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 691849-26-0 CAPLUS
 CN 4-Pyridazinecarboxamide, N-[(3,5-dichlorophenyl)methyl]-2,3-dihydro-6-(4-hydroxy-3-pyridinyl)-3-oxo- (9CI) (CA INDEX NAME)




RN 691849-27-1 CAPLUS
 CN 4-Pyridazinecarboxamide, N-butyl-2,3-dihydro-6-(4-hydroxy-3-pyridinyl)-3-oxo- (9CI) (CA INDEX NAME)




RN 691849-28-2 CAPLUS
 CN 4-Pyridazinecarboxamide, 2,3-dihydro-6-(4-hydroxy-3-pyridinyl)-3-oxo-N-(3-pyridinylmethyl)- (9CI) (CA INDEX NAME)


L4 ANSWER 3 OF 24 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 691849-32-8 CAPLUS
 CN 4-Pyridazinecarboxamide, 2,3-dihydro-N-[(4-hydroxyphenyl)methyl]-6-(4-hydroxy-3-pyridinyl)-3-oxo- (9CI) (CA INDEX NAME)




RN 691849-33-9 CAPLUS
 CN Benzeneacetamide, 2,4-dichloro-N-[2,3-dihydro-3-oxo-6-(4-pyridinyl)-4-pyridazinyl]- (9CI) (CA INDEX NAME)



RN 691849-34-0 CAPLUS
 CN 4-Pyridazinecarboxamide, N-[(2,4-dichlorophenyl)methyl]-2,3-dihydro-3-oxo-6-(4-pyrimidinyl)- (9CI) (CA INDEX NAME)


L4 ANSWER 3 OF 24 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 4 OF 24 CAPLUS COPYRIGHT 2005 ACS on STN


ACCESSION NUMBER: 2004:205958 CAPLUS
DOCUMENT NUMBER: 142:93705
TITLE: Product class 8: pyridazines
AUTHOR(S): Haider, N.; Holzer, W.
CORPORATE SOURCE: Germany
SOURCE: Science of Synthesis (2004), 16, 125-249
CODEN: SSCYJ9
PUBLISHER: Georg Thieme Verlag
DOCUMENT TYPE: Journal; General Review
LANGUAGE: English
AB A review. Methods of preparing pyridazines are reviewed including cyclization, ring transformation, aromatization, and substituent modification.
IT 87769-56-0
RL: RCT (Reactant); RACT (Reactant or reagent)
(review of preparation of pyridazines via cyclization, ring transformation, aromatization, and substituent modification)
RN 87769-56-0 CAPLUS
CN 4-Pyridazinecarboxamide, 2,3-dihydro-3-oxo-6-phenyl- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 720 THERE ARE 720 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 5 OF 24 CAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 2003:293627 CAPLUS
DOCUMENT NUMBER: 139:94783
TITLE: 5-Aryl-pyrazolo[3,4-b]pyridazines: potent inhibitors of glycogen synthase kinase-3 (GSK-3)
AUTHOR(S): Witherington, Jason; Bordas, Vincent; Haigh, David; Hickey, Deirdre M. B.; Ife, Robert J.; Rawlings, Anthony D.; Slingsby, Brian P.; Smith, David G.; Ward, Robert W.
CORPORATE SOURCE: Neurology Centre of Excellence for Drug Discovery, Department of Medicinal Chemistry, GlaxoSmithKline Research Limited, Harlow, CM19 5AW, UK
SOURCE: Bioorganic & Medicinal Chemistry Letters (2003), 13(9), 1581-1584
CODEN: BMCLE8; ISSN: 0960-894X
PUBLISHER: Elsevier Science B.V.
DOCUMENT TYPE: Journal
LANGUAGE: English
OTHER SOURCE(S): CASREACT 139:94783
AB Introduction of a nitrogen atom into the 6-position of a series of pyrazolo[3,4-b]pyridines led to a dramatic improvement in the potency of GSK-3 inhibition. Rationalisation of the binding mode suggested participation of a putative structural water mol., which was subsequently confirmed by X-ray crystallog.
IT 87769-56-0P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(arylpyrazolopyridazines as potent inhibitors of glycogen synthase kinase-3)
RN 87769-56-0 CAPLUS
CN 4-Pyridazinecarboxamide, 2,3-dihydro-3-oxo-6-phenyl- (9CI) (CA INDEX NAME)




REFERENCE COUNT: 19 THERE ARE 19 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 6 OF 24 CAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 2002:220564 CAPLUS
DOCUMENT NUMBER: 136:263177
TITLE: Preparation of pyridazinones and triazinones exhibiting excellent inhibitory activities against AMPA receptor and/or kainate receptor
INVENTOR(S): Nagato, Satoshi; Kawano, Koki; Ito, Koichi; Norimine, Yoshihiko; Ueno, Kohshi; Hanada, Takahisa; Amino, Hiroyuki; Ogo, Makoto; Hatakeyama, Shinji; Ueno, Masataka; Groom, Anthony John; Rivers, Leanne; Smith, Terence
PATENT ASSIGNEE(S): Eisai Co., Ltd., Japan
SOURCE: PCT Int. Appl., 174 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002022587	A1	20020321	WO 2001-JP8058	20010917
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BE, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
AU 2001090229	A5	20020326	AU 2001-90229	20010917
CA 2422589	AA	20030317	CA 2001-2422589	20010917
EP 1319659	A1	20030618	EP 2001-970120	20010917
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR			
ZA 2003001537	A	20040225	ZA 2003-1537	20030225
NO 2003001232	A	20030519	NO 2003-1232	20030317
US 2003225081	A1	20031204	US 2003-380783	20030318
PRIORITY APPLN. INFO.:			JP 2000-282636	A 20000918
			JP 2000-289412	A 20000922
			JP 2000-342614	A 20001109
			GB 2001-2822	A 20010205
			GB 2001-2824	A 20010205
			WO 2001-JP8058	W 20010917

OTHER SOURCE(S): MARPAT 136:263177
GI



I


L4 ANSWER 6 OF 24 CAPLUS COPYRIGHT 2005 ACS ON STN (Continued)

AB The title compds. [I; wherein A1, A2 and A3 are each independently C3-8 cycloalkyl, C3-8 cycloalkenyl, a 5- to 14-membered nonarom. heterocyclic group, a C6-14 aromatic carbocyclic group, or a 5- to 14-membered aromatic heterocyclic group, any of which may be substituted; Q is O, S, or NH; 2 is C or N; X1, X2 and X3 are each independently a single bond, optionally substituted C1-6 alkenylene, optionally substituted C2-6 alkenylene, optionally substituted C1-6 alkynyl, or alternatively R1 and R2 may be united in such a way that CR2-ZR1 forms C=C; and R3 is hydrogen, optionally substituted C1-6 alkyl, C2-6 alkenyl, or C2-6 alkynyl, or alternatively R3 may unite with any atom on the ring A1 or A3 to form together with the atom an optionally substituted C5-8 carbocycle or an optionally substituted 5- to 8-membered heterocycle] or salts thereof, or hydrates of both are prepared. These compds. do not inhibit N-methyl-D-aspartic acid (NMDA) receptor but they are excellent inhibitors of α -amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptor and/or kainic acid receptor. They are useful for the prevention or treatment of acute neurodegenerative diseases, acute cerebral vascular disorders, head injury, spinal cord injury, nerve disorders caused by low oxygen or sugar level, chronic neurodegenerative diseases, Alzheimer's disease, Parkinson's diseases, Huntington's chorea, amyotrophic lateral sclerosis, spinocerebellar degeneration, epilepsy, hepatic encephalopathy, peripheral nerve disorder, Parkinson's syndrome, spastic hemiplegia (paralysis), pain, neuralgia, schizophrenia, anxiety, drug dependence, nausea, vomiting, urination disorder, eye sight disorder caused by glaucoma, hearing disorders caused by antibiotics, food poisoning, infectious encephalomyelitis (including HIV encephalomyelitis), cerebral vascular dementia, dementia caused by meningitis, and nerve diseases. They are also used for treatment or prevention of demyelinating diseases including encephalitis, acute disseminated encephalomyelitis, multiple sclerosis, acute multiple neuritis, Guillain-Barre syndrome, chronic inflammatory demyelinating multiple nerve disorders, Marchifava-Bignami disease, central bulbopontine breakdown, optic nerve myelitis, Devic's disease (neuromyelitis optica), Baló's disease, HIV myelopathy, HIV myelopathy, progressive white substance encephalopathy or secondary demyelinating diseases (including central nervous system erythematodes, tuberos multiple polyarteritis, Sjogren syndrome, sarcoidosis, or cerebral angitis). Thus, to a solution of 75 mg 2-(2-iodophenyl)-4-(3-pyridyl)-2,3-dihydro-5H-[1]benzopyrano[4,3-c]pyridazin-3-one in 2 mL 1-methyl-2-pyrrolidone were added 55 mg Zn(CN)2 and 5 mg tetrakis(triphenylphosphine)palladium and stirred at 100° for 1 h to give 34 mg 2-(2-cyanophenyl)-4-(3-pyridyl)-2,3-dihydro-5H-[1]benzopyrano[4,3-c]pyridazin-3-one (II). II inhibited the AMPA-induced influx of Ca into rat fetal cerebral cortex nerve cells with IC50 of 0.02 μ M.


IT 404933-57-9P, 6-Phenyl-4-(((2-morpholinoethyl)amino)carbonyl)-2H-pyridazin-3-one 404933-59-1P, 6-Phenyl-4-(((2-morpholinoethyl)amino)carbonyl)-2H-pyridazin-3-one hydrochloride
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
 (preparation of pyridazinones and triazinones exhibiting excellent inhibitory activities against AMPA receptor and/or kainate receptor for treatment or prevention of acute or chronic neurodegenerative diseases)

RN 404933-57-9 CAPLUS

L4 ANSWER 6 OF 24 CAPLUS COPYRIGHT 2005 ACS ON STN (Continued)
 CN 4-Pyridazinecarboxamide, 2,3-dihydro-N-[2-(4-morpholinyl)ethyl]-3-oxo-6-phenyl- (9CI) (CA INDEX NAME)



RN 404933-59-1 CAPLUS
 CN 4-Pyridazinecarboxamide, 2,3-dihydro-N-[2-(4-morpholinyl)ethyl]-3-oxo-6-phenyl-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

REFERENCE COUNT: 12 THERE ARE 12 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 7 OF 24 CAPLUS COPYRIGHT 2005 ACS ON STN

ACCESSION NUMBER: 1999:576914 CAPLUS
 DOCUMENT NUMBER: 131:228727
 TITLE: Preparation of pyridazine derivatives as interleukin 1 β production inhibitors
 INVENTOR(S): Ohkuchi, Masao; Kyotani, Yoshinori; Shigyo, Hiromichi; Yoshizaki, Hideo; Koshi, Tomoyuki; Kitamura, Takahiro; Matsuda, Takayuki; Oda, Soichi; Habata, Yuriko; Kotaki, Kyoto
 PATENT ASSIGNEE(S): Kowa Co., Ltd., Japan; et al.
 SOURCE: PCT Int. Appl., 112 pp.
 DOCUMENT TYPE: CODEN: PIXXD2
 LANGUAGE: Patent
 FAMILY ACC. NUM. COUNT: 1 Japanese
 PATENT INFORMATION:


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9944995	A1	19990910	WO 1999-JP925	19990226
W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, GR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, RW: GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
CA 2321254	AA	19990910	CA 1999-2321254	19990226
AU 9926414	A1	19990920	AU 1999-26414	19990226
AU 739431	B2	20011011		
EP 1061077	A1	20001220	EP 1999-906509	19990226
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI				
NZ 506144	A	20011130	NZ 1999-506144	19990226
RU 2221790	C2	20040120	RU 2000-124879	19990226
US 6403586	B1	20020611	US 2000-622897	20000831
NO 2000004353	A	20000901	NO 2000-4353	20000901
HK 1035194	A1	20040820	HK 2001-105912	20010822
PRIORITY APPLN. INFO.:			JP 1998-49396	A 19980302
			WO 1999-JP925	W 19990226

GI


L4 ANSWER 7 OF 24 CAPLUS COPYRIGHT 2005 ACS ON STN (Continued)
 halogeno; R2 represents H, lower alkyl, lower alkylthio or halogeno; R3 represents OH, CN, halogeno, lower cycloalkyl, lower alkyl or lower alkynyl optionally substituted by an optionally substituted arom. group or optionally substituted carbamoyl; R4 represents COOH, lower alkoxycarbonyl, optionally substituted carbamoyl, optionally substituted amino or optionally substituted ureido; and the dotted line means a single bond or a double bond between the carbon atoms at the 4- and 5-positions] are prepd. I are useful as preventives/remedies for immunol. diseases, inflammatory diseases, ischemic diseases, etc. In an in vitro test using cells, 2-cyclopropylmethyl-6-(4-methoxyphenyl)-4-methylcarbamoyl-2H-pyridazin-3-one showed IC50 of 0.038 μ M against lipopolysaccharide-induced interleukin 1 β prodn.

IT 243862-95-5P
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
 (preparation of pyridazine derivs. as interleukin 1 β production inhibitors)

RN 243862-95-5 CAPLUS
 CN 4-Pyridazinecarboxamide, 2,3-dihydro-6-(4-methoxyphenyl)-N-methyl-3-oxo- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 7 THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT





AB The title compds. I [R1 represents lower alkoxy, lower alkylthio or

<10/19/2005>

Habte

L4 ANSWER 8 OF 24 CAPLUS COPYRIGHT 2005 ACS on STN
 ACCESSION NUMBER: 1999:325927 CAPLUS
 DOCUMENT NUMBER: 130:338106
 TITLE: Preparation of pyrazole derivatives as adenosine A1 and A2 antagonists
 INVENTOR(S): Akahane, Atsushi; Kuroda, Satoru; Itani, Hiromichi
 PATENT ASSIGNEE(S): Fujisawa Pharmaceutical Co., Ltd., Japan
 SOURCE: PCT Int. Appl., 32 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: Japanese
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9924424	A1	19990520	WO 1998-JP4892	19981028
W: CA, CN, JP, KR, US RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
PRIORITY APPL. INFO.: JP 1997-306167 A 19971107				
OTHER SOURCE(S): MARPAT 130:338106				
GI				




AB The title compds. I [R1 and R2 may be the same or different and each represents optionally substituted aryl; R3 represents hydrogen, lower alkyl, or optionally substituted ar(lower)alkyl, and R4 represents Q1 (wherein R5 represents optionally substituted ar(lower)alkyl or lower alkanoyl(lower)alkyl), etc.], useful as adenosine A1 and A2 antagonists (no data), are prepared I may serve as preventives and/or remedies for ischemic heart diseases such as angina pectoris, peripheral vascular diseases such as claudication, cerebral ischemia, migraine, diabetes, melancholia, Parkinson's disease, etc. (no data). For example, 3,5-diphenyl-4-[2-(3-methoxybenzyl)-3-oxo-2,3-dihydropyridazin-6-yl]pyrazole was prepared

IT 224573-04-0P
 RI: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (preparation of pyrazole derivs. as adenosine A1 and A2 antagonists)

RN 224573-04-0 CAPLUS
 CN 4-Pyridazinecarboxylic acid, 2,3-dihydro-6-(1-methyl-3,5-diphenyl-1H-pyrazol-4-yl)-3-oxo-, hydrazide (9CI) (CA INDEX NAME)

L4 ANSWER 8 OF 24 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)





REFERENCE COUNT: 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 9 OF 24 CAPLUS COPYRIGHT 2005 ACS on STN
 ACCESSION NUMBER: 1997:558055 CAPLUS
 DOCUMENT NUMBER: 127:262667
 TITLE: Preparation of pyrazolo[1,5-a]pyridine derivatives as adenosine antagonists and their pharmaceutical uses
 INVENTOR(S): Kuroda, Satoshi; Itani, Hiromichi; Akahane, Atsushi
 PATENT ASSIGNEE(S): Fujisawa Pharmaceutical Co., Ltd., Japan
 SOURCE: Jpn. Kokai Tokkyo Koho, 17 pp.
 CODEN: JKKXAF
 DOCUMENT TYPE: Patent
 LANGUAGE: Japanese
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 09216883	A2	19970819	JP 1996-24146	19960209
JP 1996-24146 19960209				

PRIORITY APPL. INFO.:
 OTHER SOURCE(S): MARPAT 127:262667
 GI




AB The derivs. I [R1 = aryl; R2 = oxodihydropyridazinyl Q [R3 = H, lower alkyl, acyl-lower alkyl, acyl-lower alkanoyl-lower alkyl, (un)substituted heterocycyl, (un)substituted lower aralkyl; R4 = H, acyl, cyano, heterocycyl, lower hydroxyalkyl, (unprotected) amino; R5 = H, lower alkyl; R4 and/or R5 = substituent], pyridazinyl Q1 [R6 = halo, lower alkoxy, (un)substituted arylamino; R7 = acyl, lower hydroxyalkyl]] or their pharmaceutically acceptable salts are claimed. Also claimed are pharmaceuticals containing I or their salts and carriers. I show cognition-enhancing, analgesic, antidepressant, vasodilating, diuretic, cardiotonic, renal circulation-increasing, lipolysis-promoting, antiallergic, insulin secretion-promoting, platelet aggregation-inhibiting effects, etc., and are especially useful as cardiac infarction inhibitors, antihypertensives, renal failure inhibitors, and diuretics.

3-Propionyl-2-phenylpyrazolo[1,5-a]pyridine (0.50 g), prepared by acylation of 2-phenylpyrazolo[1,5-a]pyridine with (EtCO)2O, was successively treated with CO(CO2Et)2 at 100° for 65 h then with H2NNH2.H2O at 125° for 8 h to give 0.42 g 3-[4-(2-isopropylidenehydrazino)carbonyl-1,5-methyl-3-oxo-2,3-dihydropyridazin-6-yl]-2-phenylpyrazolo[1,5-a]pyridine.


IT 195826-98-3P 195827-00-0P 195827-01-1P
 195827-02-2P 195827-03-3P 195827-04-4P
 195827-32-8P
 RI: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (preparation of pyrazolo[1,5-a]pyridine derivs. as adenosine antagonists and their pharmaceutical uses)

RN 195826-98-3 CAPLUS


L4 ANSWER 9 OF 24 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)
 CN 4-Pyridazinecarboxylic acid, 2,3-dihydro-3-oxo-6-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-, hydrazide (9CI) (CA INDEX NAME)



RN 195827-00-0 CAPLUS
 CN 4-Pyridazinecarboxylic acid, 2,3-dihydro-3-oxo-6-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-, 2-[(1,1-dimethylethoxy)carbonyl]hydrazide (9CI) (CA INDEX NAME)



RN 195827-01-1 CAPLUS
 CN 4-Pyridazinecarboxamide, 2,3-dihydro-3-oxo-6-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-N-(3,4,5-trimethoxyphenyl)- (9CI) (CA INDEX NAME)




RN 195827-02-2 CAPLUS
 CN Glycine, N-[[2,3-dihydro-3-oxo-6-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-4-pyridazinyl]carbonyl]-, ethyl ester (9CI) (CA INDEX NAME)


<10/19/2005>

Habte


L4 ANSWER 9 OF 24 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 195827-03-3 CAPLUS
CN Glycine, N-[[2,3-dihydro-3-oxo-6-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-4-pyridazinyl]carbonyl]- (9CI) (CA INDEX NAME)




RN 195827-04-4 CAPLUS
CN 4-Pyridazinecarboxamide, 2,3-dihydro-3-oxo-6-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)- (9CI) (CA INDEX NAME)




RN 195827-32-8 CAPLUS
CN Carbamic acid, [2,3-dihydro-3-oxo-6-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-4-pyridazinyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

L4 ANSWER 9 OF 24 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)




L4 ANSWER 10 OF 24 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)

IT 150594-75-5P 150594-91-5P 150595-00-9P
150595-14-5P 150595-30-3P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation and thromboxane formation inhibiting activity of)
RN 150594-75-5 CAPLUS
CN Pentanoic acid, 5-[[[6-[4-(aminoiminomethyl)phenyl]-2,3-dihydro-3-oxo-4-pyridazinyl]carbonyl]amino]- (9CI) (CA INDEX NAME)




RN 150594-91-5 CAPLUS
CN Cyclohexanecarboxylic acid, 4-[[[6-[4-(aminoiminomethyl)phenyl]-2,3-dihydro-3-oxo-4-pyridazinyl]carbonyl]amino]-, trans- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 150595-00-9 CAPLUS
CN Pentanoic acid, 5-[[[6-[4-(aminoiminomethyl)phenyl]-2,3-dihydro-3-oxo-4-pyridazinyl]carbonyl]amino]-, methyl ester (9CI) (CA INDEX NAME)



RN 150595-14-5 CAPLUS
CN Cyclohexanecarboxylic acid, 4-[[[6-[4-(aminoiminomethyl)phenyl]-2,3-dihydro-3-oxo-4-pyridazinyl]carbonyl]amino]-, methyl ester, hydrochloride, trans- (9CI) (CA INDEX NAME)

L4 ANSWER 10 OF 24 CAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 1993:625966 CAPLUS
DOCUMENT NUMBER: 119:225966
TITLE: Preparative and biological activity of aryl substituted nitrogen containing heterocycles
INVENTOR(S): Linz, Guenter; Pieper, Helmut; Himmelsbach, Frank; Austel, Volkhard; Mueller, Thomas; Weisenberger, Johannes; Seewaldt-Becker, Elke
PATENT ASSIGNEE(S): Thomae, Dr. Karl, G.m.b.H., Germany
SOURCE: Eur. Pat. Appl., 47 pp.
DOCUMENT TYPE: Patent
LANGUAGE: German
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 537696	A1	19930421	EP 1992-117507	19921014
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, NL, PT, SE				
DE 4134467	A1	19930422	DE 1991-4134467	19911018
US 5418233	A	19950523	US 1992-961135	19921014
CA 2080748	AA	19930419	CA 1992-2080748	19921016
NO 9204027	A	19930419	NO 1992-4027	19921016
AU 9227062	A1	19930422	AU 1992-27062	19921016
AU 662930	E2	19950921		
HU 62272	A2	19930428	HU 1992-3264	19921016
JP 05221992	A2	19930831	JP 1992-277578	19921016
ZA 9207994	A	19940418	ZA 1992-7994	19921016
US 5563268	A	19961008	US 1995-375084	19950119
PRIORITY APPLN. INFO.:			DE 1991-4134467	A 19911018
			US 1992-961135	A3 19921014

OTHER SOURCE(S): MARPAT 119:225966
AB The preparation of title compds. with fibrinogen-binding, thromboxane, and blood platelet aggregation inhibitor activity is claimed. Thus, reaction of 6-(4-aminophenyl)-4-[[[4-(methoxycarbonyl)butyl]aminocarbonyl]-2-methyl-(2H)-pyridazin-3-one (preparation given) with LiOH.H2O in a mixture of

THF-H2O gave 91.1 6-(4-aminophenyl)-4-[[[4-(carboxybutyl)aminocarbonyl]-2-methyl-(2H)-pyridazin-3-one. Similarly, a number of pyridazinone and pyrimidine derivs. were prepared and their biol. activity is described.

IT 150594-47-1P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation and reaction of, in preparation of thromboxane formation inhibitor)


RN 150594-47-1 CAPLUS
CN Pentanoic acid, 5-[[[6-[4-(cyanophenyl)-2,3-dihydro-3-oxo-4-pyridazinyl]carbonyl]amino]- (9CI) (CA INDEX NAME)



<10/19/2005>

Habe


L4 ANSWER 10 OF 24 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)
Relative stereochemistry.



● x HCl


RN 150595-38-3 CAPLUS
CN Cyclohexanecarboxylic acid, 4-[[[6-[4-(aminoiminomethyl)phenyl]-2,3-dihydro-3-oxo-4-pyridazinyl]carbonyl]amino]-, methyl ester, trans- (9CI) (CA INDEX NAME)

Relative stereochemistry.



L4 ANSWER 11 OF 24 CAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 1993:517098 CAPLUS
DOCUMENT NUMBER: 119:117098
TITLE: Preparation of 2-pyrrolidinone-3-acetates and analogs as cell aggregation inhibitors
INVENTOR(S): Austel, Volkhard; Eisert, Wolfgang; Himmelsbach, Frank; Linz, Guenter; Mueller, Thomas; Pieper, Helmut; Weisenberger, Johannes
PATENT ASSIGNEE(S): Thomae, Dr. Karl, G.m.b.H., Germany
SOURCE: Eur. Pat. Appl., 73 pp.
CODEN: EPXXDW
DOCUMENT TYPE: Patent
LANGUAGE: German
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 528369	A2	19930224	EP 1992-113877	19920814
EP 528369	A3	19930421		
EP 528369	B1	19991124		
DE 4127404	A1	19930225	DE 1991-4127404	19910819
AT 186906	E	19931215	AT 1992-113877	19920814
CA 2076311	AA	19930220	CA 1992-2076311	19920818
NO 9203235	A	19930222	NO 1992-3235	19920818
AU 9221119	A1	19930225	AU 1992-21119	19920818
AU 654372	B2	19941103		
JP 06025227	A2	19940201	JP 1992-219149	19920818
ZA 9206205	A	19940218	ZA 1992-6205	19920818
IL 102847	A1	19961114	IL 1992-102847	19920818
US 5455348	A	19951003	US 1993-175603	19931223
PRIORITY APPLN. INFO.:			DE 1991-4127404	A 19910819
OTHER SOURCE(S):		MARPAT 119:117098	US 1992-929870	B1 19920814
G1				



AB EYAX1X2X3X4X5B [A = (substituted) bivalent (oxo)alkyleneimino; B = NH2, C:(NH)NH2, NHC:(NH)NH2, etc.; E = CO2H, alkoxycarbonyl, etc.; X1 = bond, alkylene; X2 = bond, O, NH, SO2NH, etc.; X3, X5 = (hetero)cycloalkylene, (hetero)arylene, etc.; X4 = bond, O, CH2, CO, NH, etc.; X3X4X5 = phenylene, (CH2)3-5, etc.; Y = alkylene, NHCH2, OCH2, etc.] were prepared


L4 ANSWER 11 OF 24 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)
Thus, 4-(5-cyano-2-pyridyl)phenol (prepn. given) was condensed with (3S,5S)-3-[[[tert-butyloxycarbonyl]methyl]-5-[[methanesulfonyloxyl]methyl]-2-pyrrolidinone and the product converted in 2 steps to title compd. (3S,5S)-I which had ED50 of 0.06 µM against collagen-induced platelet aggregation in vitro.
IT 149354-60-9P 149354-62-1P 149354-79-0P
149355-41-9P 149355-53-3P 149377-23-1P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
(preparation of, as cell aggregation inhibitor)
RN 149354-60-9 CAPLUS
CN 3-Pyrrolidineacetic acid, 5-[[[6-[4-(aminoiminomethyl)phenyl]-2,3-dihydro-3-oxo-4-pyridazinyl]carbonyl]amino]methyl]-2-oxo-, (3S-trans)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 149354-62-1 CAPLUS
CN 3-Pyrrolidineacetic acid, 5-[[[6-[4-(aminoiminomethyl)phenyl]-2,3-dihydro-3-oxo-4-pyridazinyl]carbonyl]amino]methyl]-2-oxo-1-(3-phenylpropyl)-, (3S-trans)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 149354-79-0 CAPLUS
CN 3-Pyrrolidineacetic acid, 5-[[[6-[4-(aminoiminomethyl)phenyl]-2,3-dihydro-3-oxo-4-pyridazinyl]carbonyl]amino]methyl]-2-oxo-1-(3-phenylpropyl)-, methyl ester, monohydrochloride, (3S-trans)- (9CI) (CA INDEX NAME)


L4 ANSWER 11 OF 24 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)
Absolute stereochemistry.



● HCl

RN 149355-41-9 CAPLUS
CN 3-Pyrrolidineacetic acid, 5-[[[6-[4-(cyanophenyl)-2,3-dihydro-3-oxo-4-pyridazinyl]carbonyl]amino]methyl]-2-oxo-, methyl ester, (3S-trans)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 149355-53-3 CAPLUS
CN 3-Pyrrolidineacetic acid, 5-[[[6-[4-(cyanophenyl)-2,3-dihydro-3-oxo-4-pyridazinyl]carbonyl]amino]methyl]-2-oxo-1-(3-phenylpropyl)-, methyl ester, (3S-trans)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


L4 ANSWER 11 OF 24 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 149377-23-1 CAPLUS
 CN 3-Pyrrolidineacetic acid, 5-[[[6-[4-(aminoiminomethyl)phenyl]-2,3-dihydro-3-oxo-4-pyridazinyl]carbonyl]amino]methyl]-2-oxo-, methyl ester, monohydrochloride, (3S-trans)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


PAGE 1-A



PAGE 2-A

● HCl


L4 ANSWER 12 OF 24 CAPLUS COPYRIGHT 2005 ACS on STN
 ACCESSION NUMBER: 1991:206976 CAPLUS
 DOCUMENT NUMBER: 114:206976
 TITLE: Synthesis of aza analogs of amrinone
 AUTHOR(S): Singh, Baldev; Lasher, George Y.
 CORPORATE SOURCE: Dep. Med. Chem., Sterling Res. Group, Rensselaer, NY, 12144, USA
 SOURCE: Heterocycles (1990), 31(12), 2163-72
 CODEN: HICYAM; ISSN: 0385-5414
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 OTHER SOURCE(S): CASREACT 114:206976
 GI




AB The aldol condensation product I of 4-acetylpyridine and CO(CO₂Et)₂ was converted to pyridazinecarboxylic acid hydrazide II (R = CONHNH₂) (III). Curtius reaction of III gave aminopyridazine II (R = NH₂). The condensation of (4-pyridyl)glyoxal with aminomalonamide H₂NCH(CONH₂)₂ yielded pyrazinecarboxamide IV (R₁ = CONH₂) which was transformed to aminopyrazinone IV (R₁ = NH₂) by the Hofmann reaction. Curtius reaction of 1,2,4-triazinone-5-carboxylic acid V (R₂ = CO₂H) gave aminotriazinone V (R₂ = NH₂). Demethylation of methoxypyrimidine VI (R₃ = Me) gave pyrimidinol VI (R₃ = H).

IT 80843-46-5P
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
 (preparation and Curtius reaction of)
 RN 80843-46-5 CAPLUS
 CN 4-Pyridazinecarboxylic acid, 2,3-dihydro-3-oxo-6-(4-pyridinyl)-, hydrazide

L4 ANSWER 12 OF 24 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)
 (9CI) (CA INDEX NAME)




L4 ANSWER 13 OF 24 CAPLUS COPYRIGHT 2005 ACS on STN
 ACCESSION NUMBER: 1990:91460 CAPLUS
 DOCUMENT NUMBER: 112:91460
 TITLE: Pyridazines. Part 43. Pyridazine analogs of biologically active compounds. Part 5: Novel potential cardiotonics of the amrinone type
 AUTHOR(S): Haider, N.; Heinisch, G.; Offenberger, Sigrid
 CORPORATE SOURCE: Inst. Pharm. Chem., Univ. Vienna, Vienna, A-1090, Austria
 SOURCE: Pharmazie (1989), 44(9), 598-601
 CODEN: PHARAT; ISSN: 0031-7144
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 GI



AB Preparation of a series of novel pyridazine derivs. structurally related to bipyrindine cardiotonics, starting from 4-methylpyridazine or 4-acetylpyridazine, resp., is described. As observed with I, II and III, an enhancement of in vitro cardiotonic activity was associated with the replacement of one or both pyridine subunit(s) in amrinone or milrinone by a 1,2-diazine system.


IT 125375-18-0P
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
 (preparation and Hofmann degradation of)
 RN 125375-18-0 CAPLUS
 CN [3,4'-Bipyridazine]-5-carboxamide, 1,6-dihydro-6-oxo- (9CI) (CA INDEX NAME)



L4 ANSWER 14 OF 24 CAPLUS COPYRIGHT 2005 ACS on STN
 ACCESSION NUMBER: 1989:497259 CAPLUS
 DOCUMENT NUMBER: 111:97259
 TITLE: Preparation of phenylpyridazinone derivatives as cardiotonics and antihypertensives
 INVENTOR(S): Sircar, Ila; Bristol, James A.
 PATENT ASSIGNEE(S): Warner-Lambert Co., USA
 SOURCE: U.S., 19 pp. Cont.-in-part of U.S. Ser. No. 407,973.
 CODEN: USXXAM
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 3
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 4734415	A	19880329	US 1983-477695	19830322
US 4353905	A	19821012	US 1981-302181	19810917
PRIORITY APPLN. INFO.:			US 1981-302181	A2 19810917
			US 1982-402488	A2 19820727
			US 1982-407973	A2 19820813


OTHER SOURCE(S): CASREACT 111:97259; MARPAT 111:97259
 GI




AB The title compds. [I; dotted line represents single or double bond; X = O, S; R2 = H, lower alkyl; R3 = H, lower alkyl; when dotted line represents a single bond, R3 = di lower alkyl; R4 = H, lower alkyl; or when dotted line represents a double bond, R4 = H, lower alkylamino, cyano, OH, CH2OH, CONRSR6, etc.; R3R4 = atoms to complete a carbocycle of 3-6 atoms; R5, R6 = H, alkyl; Y = H, halo, lower alkyl, alkoxy etc.; A = R1Z; R1 = N-attached, (un)substituted, 5- or 6-membered heterocyclyl, optionally containing other hetero atoms; Z = bond, (CH2)nO in the 4-position; n = 2-5] and their pharmaceutically acceptable salts, useful as cardiotonics and antihypertensives, were prepared

IT 97150-66-8P
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
 (preparation and reaction of, in preparation of cardiotonic and antihypertensive)
 RN 97150-66-8 CAPLUS
 CN 4-Pyridazinecarboxylic acid, 2,3-dihydro-6-[4-(1H-imidazol-1-yl)phenyl]-3-oxo-, hydrazide (9CI) (CA INDEX NAME)


L4 ANSWER 14 OF 24 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



IT 97150-66-8
 RL: RCT (Reactant); RACT (Reactant or reagent)
 (reaction of, in preparation of pyridazinone cardiotonic and antihypertensive)
 RN 97150-66-8 CAPLUS
 CN 4-Pyridazinecarboxylic acid, 2,3-dihydro-6-[4-(1H-imidazol-1-yl)phenyl]-3-oxo-, hydrazide (9CI) (CA INDEX NAME)




L4 ANSWER 16 OF 24 CAPLUS COPYRIGHT 2005 ACS on STN
 ACCESSION NUMBER: 1987:598252 CAPLUS
 DOCUMENT NUMBER: 107:198252
 TITLE: Cardiotonic agents. 7. Inhibition of separated forms of cyclic nucleotide phosphodiesterase from guinea pig cardiac muscle by 4,5-dihydro-6-[4-(1H-imidazol-1-yl)phenyl]-3(2H)-pyridazinones and related compounds. Structure-activity relationships and correlation with in vivo positive inotropic activity
 AUTHOR(S): Sircar, Ila; Weishaar, Ronald E.; Kobylarz, Dianne; Moos, Walter H.; Bristol, James A.
 CORPORATE SOURCE: Dep. Chem., Warner-Lambert/Parke-Davis Pharm. Res., Ann Arbor, MI, 48105, USA
 SOURCE: Journal of Medicinal Chemistry (1987), 30(11), 1955-62
 CODEN: JMCHAR; ISSN: 0022-2623
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 OTHER SOURCE(S): CASREACT 107:198252
 GI




AB Imidazolylphenylpyrazolinone I was prepared from benzonitrile II. The structure-activity relationships of a series of 4,5-dihydro-6-[4-(1H-imidazol-1-yl)phenyl]-3(2H)-pyridazinones, e.g., III (R = H, Me, CH2Ph, CH2CH2OH, CH2CH2OAc; R1 = H, Me, NH2, CONH2; R2 = H, Me, Et; R3 = H, Me, SH, SMe, SOMe, Et), I and related compds. were investigated for the in vivo inhibition of different forms of cyclic nucleotide phosphodiesterase (PDE) isolated from guinea pig ventricular muscle. With few exceptions, these 4,5-dihydropyridazinones were potent inhibitors of cardiac type III phosphodiesterase, which is a low Km, cAMP specific form of the enzyme. The inhibitory effects on cardiac type I and type II phosphodiesterase, both of which hydrolyze cAMP as well as cyclic GMP, were minimal. The most selective PDE III inhibitor was CI-930 III (R = R1 = R3 = H, R2 = Me) (IV), the 5-Me analog of imazodan III (R = R3 = H) with an ED50 of 0.6 µM. The most potent inhibitor of PDE III was the 4,5,6,7-tetrahydrobenzimidazole analog of IV, with an ED50 of 0.15 µM. The structural features that impart both selectivity for inhibiting type III phosphodiesterase and potency of inhibition and correlations between in vitro PDE inhibitory potency, in vivo pos. inotropic potency, and physicochem. properties are discussed.

IT 97150-66-8 97150-67-9
 RL: RCT (Reactant); RACT (Reactant or reagent)
 (phosphodiesterase inhibitory activity of)
 RN 97150-66-8 CAPLUS
 CN 4-Pyridazinecarboxylic acid, 2,3-dihydro-6-[4-(1H-imidazol-1-yl)phenyl]-3-oxo-, hydrazide (9CI) (CA INDEX NAME)




AB Forty-seven substituted analogs of minaprine, e.g., I, were synthesized and tested for their potential antidepressant, serotonergic, and dopaminergic activities. The structure-activity relationships show that dopaminergic and serotonergic activities can be dissociated. Serotonergic activity appears to be correlated mainly with the substituent in the 4-position of the pyridazine ring whereas the dopaminergic activity appears to be dependent on the presence, or in the formation, of a para-hydroxylated aryl ring in the 6-position of the pyridazine ring.


IT 87769-56-0P
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
 (preparation and chlorination of)
 RN 87769-56-0 CAPLUS
 CN 4-Pyridazinecarboxamide, 2,3-dihydro-3-oxo-6-phenyl- (9CI) (CA INDEX NAME)



L4 ANSWER 16 OF 24 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)




RN 97150-67-9 CAPLUS
 CN 4-Pyridazinecarboxamide, 2,3-dihydro-6-[4-(1H-imidazol-1-yl)phenyl]-3-oxo-
 (9CI) (CA INDEX NAME)




L4 ANSWER 17 OF 24 CAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 1987:213880 CAPLUS
 DOCUMENT NUMBER: 106:213880
 TITLE: The reaction of pyridazinones with nucleophiles. An unusual reaction with cyanide
 AUTHOR(S): Badger, Edward W.; Moos, Walter H.
 CORPORATE SOURCE: Dep. Chem., Warner-Lambert/Parke-Davis Pharm. Res., Ann Arbor, MI, 48105, USA
 SOURCE: Journal of Heterocyclic Chemistry (1986), 23(5), 1515-17
 CODEN: JHTCAD; ISSN: 0022-152X
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 OTHER SOURCE(S): CASREACT 106:213880
 GI




AB Studies on the synthesis of pyridazinone analogs of pyridone cardiotonics are reported. The synthetic scheme involves the reaction of pyridazinones and chloropyridazinones I (R = H, R1 = H, Cl) with nucleophiles. Addition occurred twice with cyanide as the nucleophile, thus providing a novel dicyanopyridazinone I (R = R1 = cyano).

IT 97150-66-8
 RL: RCT (Reactant); RACT (Reactant or reagent)
 (Curtis rearrangement of)
 RN 97150-66-8 CAPLUS
 CN 4-Pyridazinecarboxylic acid, 2,3-dihydro-6-[4-(1H-imidazol-1-yl)phenyl]-3-oxo-, hydrazide (9CI) (CA INDEX NAME)




L4 ANSWER 18 OF 24 CAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 1985:560462 CAPLUS
 DOCUMENT NUMBER: 103:160462
 TITLE: Cardiotonic agents. 2. Synthesis and structure-activity relationships of 4,5-dihydro-6-[4-(H-imidazol-1-yl)phenyl]-3(2H)-pyridazinones: a new class of positive inotropic agents
 AUTHOR(S): Sircar, Ila; Duell, Bradley L.; Bobowski, George; Bristol, James A.; Evans, Dale B.
 CORPORATE SOURCE: Dep. Chem., Warner-Lambert/Parke-Davis Pharm. Res., Ann Arbor, MI, 48105, USA
 SOURCE: Journal of Medicinal Chemistry (1985), 28(10), 1405-13
 CODEN: JMCMAR; ISSN: 0022-2623
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 OTHER SOURCE(S): CASREACT 103:160462
 GI



AB A series of 4,5-dihydro-6-[4-(1H-imidazol-1-yl)phenyl]-3(2H)-pyridazinones and related compds. were synthesized and evaluated for pos. inotropic activity. Most members of this series produced dose-related increases in myocardial contractility that were associated with relative minor increases in heart rate and decreases in systemic arterial blood pressure. Introduction of a Me substituent at the 5-position of pyridazinone I (R = H) (II) produced the most potent compound in this series, I (R = Me) (III). Compound II is more potent than aminone whereas compound III is more potent than milrinone. The inotropic effects of II and III are not mediated via stimulation of β -adrenergic receptors. Selective inhibition of cardiac phosphodiesterase fraction III represents the principal component of the pos. inotropic action of II and III.

IT 97150-67-9P
 RL: RAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
 (preparation and inotropic activity of)
 RN 97150-67-9 CAPLUS
 CN 4-Pyridazinecarboxamide, 2,3-dihydro-6-[4-(1H-imidazol-1-yl)phenyl]-3-oxo-
 (9CI) (CA INDEX NAME)




<10/19/2005>

Habte


L4 ANSWER 19 OF 24 CAPLUS COPYRIGHT 2005 ACS on STN
 ACCESSION NUMBER: 1985:62255 CAPLUS
 DOCUMENT NUMBER: 102:62255
 TITLE: Pyridazine derivative having a psychotropic action and medicines containing them
 INVENTOR(S): Kan, Jean Paul; Biziere, Kathleen; Wermuth, Camille Georges
 PATENT ASSIGNEE(S): Sanofi, Fr.
 SOURCE: Fr. Demande, 12 pp.
 CODEN: FRXXBL
 DOCUMENT TYPE: Patent
 LANGUAGE: French
 FAMILY ACC. NUM. COUNT: 2
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
FR 2540115	A1	19840803	FR 1983-1366	19830128
FR 2540115	B1	19850607		
US 4565814	A	19860121	US 1984-571696	19840118
CA 1218655	A1	19870303	CA 1984-445482	19840118
DK 8400259	A	19840729	DK 1984-259	19840120
DK 159969	B	19910107		
DK 159969	C	19910527		
ZA 8400500	A	19840829	ZA 1984-500	19840123
IL 70755	A1	19870331	IL 1984-70755	19840123
AU 8423728	A1	19840802	AU 1984-23728	19840124
AU 566352	B2	19871015		
ES 529108	A1	19841001	ES 1984-529108	19840124
EP 116494	A1	19840822	EP 1984-400157	19840125
EP 116494	B1	19880127		
R: AT, BE, CH, DE, FR, GB, IT, LI, LU, NL, SE				
AT 32220	E	19880215	AT 1984-400157	19840125
FI 8400349	A	19840729	FI 1984-349	19840127
FI 77453	B	19881130		
FI 77453	C	19890310		
NO 8400329	A	19840730	NO 1984-329	19840127
HU 33148	O	19841029	HU 1984-378	19840127
HU 192975	B	19870828		
DD 215542	A5	19841114	DD 1984-259679	19840127
SU 1274623	A3	19861130	SU 1984-3697653	19840127
PL 143994	B1	19880430	PL 1984-245932	19840127
CS 274405	B2	19910411	CS 1984-614	19840127
JP 59141565	A2	19840814	JP 1984-14185	19840128
US 4631280	A	19861223	US 1985-73580	19850520
DK 8906215	A	19891208	DK 1989-6215	19891208
DK 162218	B	19910930		
DK 162218	C	19920302		
DK 8906216	A	19891208	DK 1989-6216	19891208
DK 162219	B	19910930		
DK 162219	C	19920302		
PRIORITY APPLN. INFO.:				
		FR 1983-1366	A	19830128
		FR 1983-18433	A	19830128
		US 1984-571696	A3	19840118
		EP 1984-400157	A	19840125
OTHER SOURCE(S): CASREACT 102:62255				


L4 ANSWER 19 OF 24 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)




AB 3-[2-(4-Morpholinyl)ethylamino]-6-phenyl-4-pyridazinecarbonitrile dihydrochloride (I) was prepared, and it showed antidepressant activity. The cyclocondensation of PhCOCH2CH(CO2Et)2 with NH4 gave pyridazinone derivative II, which was brominated and dehydrobrominated to give ester III (R = OEt); the latter was converted to amide III (R = NH2). The amide was treated with POCl3 to give 3-chloro-6-phenyl-4-pyridazinecarbonitrile, and the product was treated with 4-(2-aminoethyl)morpholine and HCl to give I.
 IT 87769-56-OP
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
 RN 87769-56-0 CAPLUS
 CN 4-Pyridazinecarboxamide, 2,3-dihydro-3-oxo-6-phenyl- (9CI) (CA INDEX NAME)




L4 ANSWER 20 OF 24 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)




IT 94011-51-5 94011-52-6 94011-53-7
 94011-54-8 94011-55-9 94011-56-0
 94011-57-1 94011-58-2 94011-59-3
 94011-60-6 94011-61-7 94011-62-8
 94011-63-9
 RL: RCT (Reactant); RACT (Reactant or reagent)
 RN 94011-51-5 CAPLUS
 CN 4-Pyridazinecarboxamide, 6-(4-chlorophenyl)-2,3-dihydro-3-oxo- (9CI) (CA INDEX NAME)



RN 94011-52-6 CAPLUS
 CN 4-Pyridazinecarboxamide, 6-cyclohexyl-2,3-dihydro-3-oxo- (9CI) (CA INDEX NAME)




RN 94011-53-7 CAPLUS
 CN 4-Pyridazinecarboxamide, 6-(2,4-dichlorophenyl)-2,3-dihydro-3-oxo- (9CI) (CA INDEX NAME)




AB 3-Amino-4-pyridazinecarbonitriles I [one of R and R1 is H or alkyl, and the other is H, alkyl, cycloalkyl, Ph or substituted Ph, naphthyl, thienyl, 3-indolyl; Z = CH2CH2, CH2CHMe, (CH2)3; R2 = H and R3 = H, CH2CH2OH, or NR2R3 = 4-morpholinyl, 3-oxo-4-morpholinyl], which were prepared, showed psychotropic activity. 3-Chloro-6-phenyl-4-pyridazinecarbonitrile was heated with 4-(2-aminoethyl)morpholine in BuOH to give I (R = Ph, R1 = H, Z = CH2CH2, NR2R3 = 4-morpholinyl).
 IT 87769-56-OP
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
 RN 87769-56-0 CAPLUS
 CN 4-Pyridazinecarboxamide, 2,3-dihydro-3-oxo-6-phenyl- (9CI) (CA INDEX NAME)


L4 ANSWER 20 OF 24 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 94011-54-8 CAPLUS
 CN 4-Pyridazinecarboxamide, 6-(2-chlorophenyl)-2,3-dihydro-3-oxo- (9CI) (CA INDEX NAME)




RN 94011-55-9 CAPLUS
 CN 4-Pyridazinecarboxamide, 2,3-dihydro-3-oxo-6-(2-thienyl)- (9CI) (CA INDEX NAME)




RN 94011-56-0 CAPLUS
 CN 4-Pyridazinecarboxamide, 2,3-dihydro-6-(4-methoxyphenyl)-3-oxo- (9CI) (CA INDEX NAME)


L4 ANSWER 20 OF 24 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)




RN 94011-57-1 CAPLUS
 CN 4-Pyridazinecarboxamide, 6-(3,4-dichlorophenyl)-2,3-dihydro-3-oxo- (9CI) (CA INDEX NAME)



RN 94011-58-2 CAPLUS
 CN 4-Pyridazinecarboxamide, 2,3-dihydro-6-(2-naphthalenyl)-3-oxo- (9CI) (CA INDEX NAME)




RN 94011-59-3 CAPLUS
 CN 4-Pyridazinecarboxamide, 2,3-dihydro-6-(4-nitrophenyl)-3-oxo- (9CI) (CA INDEX NAME)




L4 ANSWER 20 OF 24 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)


RN 94011-60-6 CAPLUS
 CN 4-Pyridazinecarboxamide, 2,3-dihydro-6-(4-methylphenyl)-3-oxo- (9CI) (CA INDEX NAME)



RN 94011-61-7 CAPLUS
 CN 4-Pyridazinecarboxamide, 2,3-dihydro-3-oxo-6-[4-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)




RN 94011-62-8 CAPLUS
 CN 4-Pyridazinecarboxamide, 2,3-dihydro-3-oxo-6-[3-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)




RN 94011-63-9 CAPLUS
 CN 4-Pyridazinecarboxamide, 6-(4-cyanophenyl)-2,3-dihydro-3-oxo- (9CI) (CA INDEX NAME)


L4 ANSWER 20 OF 24 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)




L4 ANSWER 21 OF 24 CAPLUS COPYRIGHT 2005 ACS on STN
 ACCESSION NUMBER: 1984:630453 CAPLUS
 DOCUMENT NUMBER: 101:230453
 TITLE: Novel amination of 6-aryl-3(2H)-pyridazinones with hydrazine
 AUTHOR(S): Singh, Baldev
 CORPORATE SOURCE: Sterling-Winthrop Res. Inst., Rensselaer, NY, 12144, USA
 SOURCE: Heterocycles (1984), 22(8), 1801-4
 CODEN: HTCYAM; ISSN: 0385-5414
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 OTHER SOURCE(S): CASREACT 101:230453
 GI




AB Aminopyridazinones I (R = H, Me; R1 = 4-pyridyl, 4-H2NCGH4, 4-HOCCGH4) were prepared from II (R2 = 4-pyridyl, 4-ACNHC6H4, 4-HOCCGH4). II (R = H, R2 = 4-pyridyl) was heated with N2H4 to give I (R = H, R1 = 4-pyridyl).
 IT 80843-46-5
 RL: RCT (Reactant); RACT (Reactant or reagent)
 (attempted rearrangement of, with hydrazine)
 RN 80843-46-5 CAPLUS
 CN 4-Pyridazinecarboxylic acid, 2,3-dihydro-3-oxo-6-(4-pyridinyl)-, hydrazide (9CI) (CA INDEX NAME)



L4 ANSWER 22 OF 24 CAPLUS COPYRIGHT 2005 ACS on STN
 ACCESSION NUMBER: 1984:174757 CAPLUS
 DOCUMENT NUMBER: 100:174757
 TITLE: Synthesis of 4-amino-6-phenyl-3(2H)-pyridazinones: a general procedure
 AUTHOR(S): Sircar, Ila
 CORPORATE SOURCE: Dep. Chem., Warner-Lambert/Parke-Davis Pharm. Res., Ann Arbor, MI, 48105, USA
 SOURCE: Journal of Heterocyclic Chemistry (1983), 20(6), 1473-6
 CODEN: JHTCAD; ISSN: 0022-152X
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 OTHER SOURCE(S): CASREACT 100:174757
 GI




AB 3,4-Dichloro-6-phenylpyridazine (I) was prepared by treating 2-benzyl-4,5-dihydro-6-phenyl-3(2H)-pyridazinone with PC15-POC13. I was aminated to give II [R = NMe2, NH(CH2)3NMe2, NHBu, 4-methylpiperizino, morpholino, thiomorpholino; R1 = Cl] which were hydrolyzed with acid to II (R1 = OH).
 IT 87769-56-0P
 RL: SPN (Synthetic preparation); PREP (Preparation)
 (preparation and Hofmann degradation of)
 RN 87769-56-0 CAPLUS
 CN 4-Pyridazinecarboxamide, 2,3-dihydro-3-oxo-6-phenyl- (9CI) (CA INDEX NAME)




L4 ANSWER 23 OF 24 CAPLUS COPYRIGHT 2005 ACS on STN
 ACCESSION NUMBER: 1983:594988 CAPLUS
 DOCUMENT NUMBER: 99:194988
 TITLE: Substituted 6-phenyl-3(2H)-pyridazinones useful as cardiotonic agents
 INVENTOR(S): Sircar, Ila
 PATENT ASSIGNEE(S): Warner-Lambert Co., USA
 SOURCE: U.S., 6 pp.
 CODEN: USXXAM
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 2
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 4404203	A	19830913	US 1981-263643	19810514
US 4397854	A	19830809	US 1981-325719	19811130
			US 1981-263643	A2 19810514

 PRIORITY APPLN. INFO.:
 OTHER SOURCE(S): CASREACT 99:194988
 GI



AB The cardiotonic title compds. I [R = H, alkyl, PhCH2, Ph; R1 = H, R2 = CF3, PhCH2, cyano, CO2H, CONR52 (R5 = H, alkyl), CH2NR52, CH2OH, NR52; R2 = H, R1 = CF3, cyano, CONR52, CH2NR52, NR52; R3, R4 = H, halo, alkyl, alkoxy, HO, PhO, sulfonamido; dotted line represents single or double bond] were prepared. Thus, 89 g PhCOCH2CH2CO2H was cyclized with H2NNH2.H2O in EtOH to give 75.6 g 6-phenyl-4,5-dihydro-3(2H)-pyridazinone, which was dehydrogenated by treatment with Br to give 60 g 6-phenyl-3(2H)-pyridazinone (II). At 0.1 mg/kg II increased cardiac contractility by 9.2% in dogs.
 IT 87769-56-0P
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
 (preparation and dehydration of)
 RN 87769-56-0 CAPLUS
 CN 4-Pyridazinecarboxamide, 2,3-dihydro-3-oxo-6-phenyl- (9CI) (CA INDEX NAME)




L4 ANSWER 23 OF 24 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)

L4 ANSWER 24 OF 24 CAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 1982:85571 CAPLUS
DOCUMENT NUMBER: 96:85571
TITLE: 4-Substituted 6-(pyridinyl)-3(2H)-pyridazinones,
intermediates in their production and their use as
cardiotonic agents
INVENTOR(S): Leshner, George Yohe; Dickinson, William Borden; Singh,
Baldev
PATENT ASSIGNEE(S): Sterling Drug Inc., USA
SOURCE: Fr. Demande, 36 pp.
CODEN: FRXXBL
DOCUMENT TYPE: Patent
LANGUAGE: French
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
FR 2481284	A1	19811030	FR 1981-8251	19810424
US 4304776	A	19811208	US 1980-144697	19800428
US 4305943	A	19811215	US 1980-144563	19800428
US 4338446	A	19820706	US 1981-238483	19810226
US 4346221	A	19820824	US 1981-239566	19810302
AU 8169724	A1	19811105	AU 1981-69724	19810422
GB 2075500	A	19811118	GB 1981-12638	19810423
GB 2075500	B2	19840606		
ZA 8102652	A	19820526	ZA 1981-2652	19810423
BE 888566	A1	19811027	BE 1981-10209	19810427
DK 8101866	A	19811029	DK 1981-1866	19810427
FI 8101304	A	19811029	FI 1981-1304	19810427
NO 8101420	A	19811029	NO 1981-1420	19810427
SE 8102660	A	19811029	SE 1981-2660	19810427
ES 501665	A1	19830101	ES 1981-501665	19810427
CA 1166253	A1	19840424	CA 1981-376309	19810427
CA 1166254	A1	19840424	CA 1981-376317	19810427
NL 8102077	A	19811116	NL 1981-2077	19810428
JP 56167684	A2	19811223	JP 1981-65103	19810428
DE 3116861	A1	19820114	DE 1981-3116861	19810428
PRIORITY APPLN. INFO.:			US 1980-144563	A 19800428
OTHER SOURCE(S):			US 1980-144697	A 19800428
GI				

L4 ANSWER 24 OF 24 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



AB Cardiotonic (no data), pyridylpyridazinones I (R = H, alkyl, hydroxyalkyl, R1 = NH2, CONH2, CO2H, CONHNH2, alkoxycarbonyl) were prepared. Thus 4-acetylpyridine was treated with OC(CO2Et)2 to give II which was cyclized with N2H4 and dehydrated to give III (R1 = CO2Et). The ester was converted to the hydrazide and then the azide which was subjected to Curtius rearrangement, hydrolysis, and decarboxylation to give III (R1 = NH2).

IT 80843-46-5p

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

RN 80843-46-5 CAPLUS

CN 4-Pyridazinecarboxylic acid, 2,3-dihydro-3-oxo-6-(4-pyridinyl)-, hydrazide (9CI) (CA INDEX NAME)

